AbCellera Biologics (ABCL) Other Operating Expenses (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly Other Operating Expenses came in at $6.8 million in Q1 2026, up 28.27% YoY from $5.3 million in Q1 2025, and up 359.61% on a QoQ basis from -$2.6 million in Q4 2025.
AbCellera Biologics (ABCL) Other Operating Expenses (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of Other Operating Expenses data on file, last reported at $6.8 million in Q1 2026.
- Quarterly Other Operating Expenses rose 28.27% year-over-year to $6.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73.0 million (up 40.17% YoY) and the FY2025 annual result came in at $22.2 million, down 75.6% from the prior year.
- Other Operating Expenses rose to $6.8 million in Q1 2026, from -$2.6 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $77.9 million in Q3 2024 to a low of -$108.6 million in Q4 2024.
- A 5-year average of $15.5 million and a median of $9.3 million in 2023 frame the typical range for Other Operating Expenses.
- The widest YoY moves for Other Operating Expenses: up 746.33% in 2024, down 2964.84% in 2024.
- Tracing ABCL's Other Operating Expenses over 5 years: stood at $18.1 million in 2022, then tumbled by 119.62% to -$3.5 million in 2023, then tumbled by 2964.84% to -$108.6 million in 2024, then jumped by 97.57% to -$2.6 million in 2025, then jumped by 359.61% to $6.8 million in 2026.
- The last three Other Operating Expenses figures came in at $6.8 million (Q1 2026), -$2.6 million (Q4 2025), and $60.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.99 Mn |
| Mar 31, 2026 | 6.84 Mn |
| Dec 31, 2025 | -2.63 Mn |
| Sep 30, 2025 | 60.28 Mn |
| Jun 30, 2025 | 8.48 Mn |
| Mar 31, 2025 | 5.33 Mn |
| Dec 31, 2024 | -108.62 Mn |
| Sep 30, 2024 | 77.89 Mn |
| Jun 30, 2024 | 77.45 Mn |
| Mar 31, 2024 | 8.21 Mn |
| Dec 31, 2023 | -3.54 Mn |
| Sep 30, 2023 | 9.20 Mn |
| Jun 30, 2023 | 9.45 Mn |
| Mar 31, 2023 | 9.29 Mn |
| Dec 31, 2022 | 18.06 Mn |
| Sep 30, 2022 | 23.27 Mn |
| Jun 30, 2022 | 13.22 Mn |
| Mar 31, 2022 | 51.00 Mn |
| Dec 31, 2021 | -12.09 Mn |
| Sep 30, 2021 | 4.88 Mn |